Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $414000.0.

  • Northwest Biotherapeutics' Amortization of Deferred Charges fell 2486.39% to $414000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 740.93%. This contributed to the annual value of $2.5 million for FY2024, which is 438.45% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Amortization of Deferred Charges stood at $414000.0 for Q3 2025, which was down 2486.39% from $525000.0 recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Amortization of Deferred Charges peaked at $1.1 million during Q1 2021, and registered a low of $231000.0 during Q2 2021.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $576000.0 (2024), whereas its average is $589105.3.
  • Over the last 5 years, Northwest Biotherapeutics' Amortization of Deferred Charges had its largest YoY gain of 22827.99% in 2021, and its largest YoY loss of 6835.62% in 2021.
  • Over the past 5 years, Northwest Biotherapeutics' Amortization of Deferred Charges (Quarter) stood at $580000.0 in 2021, then increased by 13.79% to $660000.0 in 2022, then plummeted by 44.55% to $366000.0 in 2023, then skyrocketed by 134.43% to $858000.0 in 2024, then plummeted by 51.75% to $414000.0 in 2025.
  • Its last three reported values are $414000.0 in Q3 2025, $525000.0 for Q2 2025, and $334000.0 during Q1 2025.